Management of newly-diagnosed metastatic hormone-sensitive prostate cancer: a survey of UK uro-oncologists
Management of newly-diagnosed metastatic hormone-sensitive prostate cancer: a survey of UK uro-oncologists
 
  AIM: To explore the practice and views of uro-oncologists in the UK regarding their use of chemotherapy and androgen receptor-targeted agents (ARTAs) in patients with newly-diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).
METHODS: An expert-devised paper or online questionnaire was completed by members of the British Uro-oncology Group.
RESULTS: All respondents stated that they would offer patients with newly-diagnosed mHSPC docetaxel and androgen deprivation therapy (ADT) if they were sufficiently fit to receive chemotherapy (this was the only option available at the time of the survey); 64% would strongly recommend docetaxel for those with high-volume metastatic disease and 31% for those with low-volume disease. Hypothetically, if both docetaxel and ARTAs were available in the UK for mHSPC, almost 65% of respondents would recommend an ARTA with ADT to these patients in at least one-half of all cases, with the strongest recommendations to patients with high-risk disease. Imaging for response was conducted according to suspicion of disease progression, regardless of treatment, with the minority of clinicians recommending routine imaging. If a choice of therapy was available, docetaxel would be more likely to be offered to patients with liver or lung metastases, and ARTAs to patients with bone or lymph node only metastases. Almost all respondents would offer local radiotherapy to the primary tumour in patients with low-volume disease.
CONCLUSION: All the UK uro-oncologists those surveyed stated that they would offer docetaxel in combination with ADT to all newly-diagnosed patients with mHSPC if fit enough for chemotherapy. ARTAs would be offered to many patients if available, especially those with high-risk disease or those unfit to receive chemotherapy. Scanning was typically conducted following treatment only at suspicion of disease progression.
e13874
  
    
      Bahl, Amit
      
        98bd0c14-6b4e-4d78-882e-42bfc42e7005
      
     
  
    
      Crabb, Simon
      
        bcd1b566-7677-4f81-8429-3ab0e85f8373
      
     
  
    
      Ford, Dan
      
        b1c4be1a-b812-4270-a8ce-5a584eb5980e
      
     
  
    
      Jones, Rob
      
        cd0b6c2a-900e-40a6-8011-2cebf14d632e
      
     
  
    
      Malik, Zaf
      
        3fad1eb7-1476-4ce9-8371-a4cbbb3bee10
      
     
  
    
      Mazhar, Danish
      
        f336725b-833e-46a0-bb88-31152f2c5712
      
     
  
    
      O'Sullivan, Joe
      
        8b3b7124-40d9-4fe9-86c1-c0e62e655980
      
     
  
    
      Payne, Heather
      
        aef578cc-b692-4435-b460-7b906b185bd0
      
     
  
  
   
  
  
    
    
  
  
    
      Bahl, Amit
      
        98bd0c14-6b4e-4d78-882e-42bfc42e7005
      
     
  
    
      Crabb, Simon
      
        bcd1b566-7677-4f81-8429-3ab0e85f8373
      
     
  
    
      Ford, Dan
      
        b1c4be1a-b812-4270-a8ce-5a584eb5980e
      
     
  
    
      Jones, Rob
      
        cd0b6c2a-900e-40a6-8011-2cebf14d632e
      
     
  
    
      Malik, Zaf
      
        3fad1eb7-1476-4ce9-8371-a4cbbb3bee10
      
     
  
    
      Mazhar, Danish
      
        f336725b-833e-46a0-bb88-31152f2c5712
      
     
  
    
      O'Sullivan, Joe
      
        8b3b7124-40d9-4fe9-86c1-c0e62e655980
      
     
  
    
      Payne, Heather
      
        aef578cc-b692-4435-b460-7b906b185bd0
      
     
  
       
    
 
  
    
      
  
  
  
  
  
  
    Bahl, Amit, Crabb, Simon, Ford, Dan, Jones, Rob, Malik, Zaf, Mazhar, Danish, O'Sullivan, Joe and Payne, Heather
  
  
  
  
   
    (2020)
  
  
    
    Management of newly-diagnosed metastatic hormone-sensitive prostate cancer: a survey of UK uro-oncologists.
  
  
  
  
    International Journal of Clinical Practice, .
  
   (doi:10.1111/ijcp.13874). 
  
  
   
  
  
  
  
  
   
  
    
    
      
        
          Abstract
          AIM: To explore the practice and views of uro-oncologists in the UK regarding their use of chemotherapy and androgen receptor-targeted agents (ARTAs) in patients with newly-diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).
METHODS: An expert-devised paper or online questionnaire was completed by members of the British Uro-oncology Group.
RESULTS: All respondents stated that they would offer patients with newly-diagnosed mHSPC docetaxel and androgen deprivation therapy (ADT) if they were sufficiently fit to receive chemotherapy (this was the only option available at the time of the survey); 64% would strongly recommend docetaxel for those with high-volume metastatic disease and 31% for those with low-volume disease. Hypothetically, if both docetaxel and ARTAs were available in the UK for mHSPC, almost 65% of respondents would recommend an ARTA with ADT to these patients in at least one-half of all cases, with the strongest recommendations to patients with high-risk disease. Imaging for response was conducted according to suspicion of disease progression, regardless of treatment, with the minority of clinicians recommending routine imaging. If a choice of therapy was available, docetaxel would be more likely to be offered to patients with liver or lung metastases, and ARTAs to patients with bone or lymph node only metastases. Almost all respondents would offer local radiotherapy to the primary tumour in patients with low-volume disease.
CONCLUSION: All the UK uro-oncologists those surveyed stated that they would offer docetaxel in combination with ADT to all newly-diagnosed patients with mHSPC if fit enough for chemotherapy. ARTAs would be offered to many patients if available, especially those with high-risk disease or those unfit to receive chemotherapy. Scanning was typically conducted following treatment only at suspicion of disease progression.
         
      
      
        
          
            
  
    Text
 mHSPC survey manuscript final for submission 130720
     - Accepted Manuscript
   
  
  
    
  
 
          
            
          
            
           
            
           
        
        
       
    
   
  
  
  More information
  
    
      e-pub ahead of print date: 30 November 2020
 
    
  
  
    
  
    
     
        Additional Information:
        This article is protected by copyright. All rights reserved.
      
    
  
    
  
    
  
    
  
    
  
    
  
    
  
  
  
    
  
    
  
    
  
  
        Identifiers
        Local EPrints ID: 445552
        URI: http://eprints.soton.ac.uk/id/eprint/445552
        
          
        
        
        
        
          PURE UUID: d1a50094-e3e0-4ade-854d-d209dc1ef61a
        
  
    
        
          
        
    
        
          
            
              
            
          
        
    
        
          
        
    
        
          
        
    
        
          
        
    
        
          
        
    
        
          
        
    
        
          
        
    
  
  Catalogue record
  Date deposited: 16 Dec 2020 17:30
  Last modified: 12 Sep 2024 04:01
  Export record
  
  
   Altmetrics
   
   
  
 
 
  
    
    
      Contributors
      
          
          Author:
          
            
            
              Amit Bahl
            
          
        
      
        
      
          
          Author:
          
            
            
              Dan Ford
            
          
        
      
          
          Author:
          
            
            
              Rob Jones
            
          
        
      
          
          Author:
          
            
            
              Zaf Malik
            
          
        
      
          
          Author:
          
            
            
              Danish Mazhar
            
          
        
      
          
          Author:
          
            
            
              Joe O'Sullivan
            
          
        
      
          
          Author:
          
            
            
              Heather Payne
            
          
        
      
      
      
    
  
   
  
    Download statistics
    
      Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
      
      View more statistics